Show simple item record

dc.contributor.authorFeliu, Jaume
dc.contributor.authorSalud Salvia, Maria Antonieta
dc.contributor.authorSafont, M. J.
dc.contributor.authorGarcía-Girón, C.
dc.contributor.authorAparicio, Jorge
dc.contributor.authorSerra, O.
dc.contributor.authorVera, R.
dc.contributor.authorCasado, Enrique
dc.contributor.authorJorge, Monica
dc.contributor.authorEscudero, P.
dc.contributor.authorBosch, Carlos
dc.contributor.authorBohn, Uriel
dc.contributor.authorPérez-Carrión, Ramon
dc.contributor.authorCarmona, Alberto
dc.contributor.authorMartínez-Marín, V.
dc.contributor.authorMaurel, Joan
dc.date.accessioned2016-03-30T07:45:15Z
dc.date.issued2014
dc.identifier.issn0007-0920
dc.identifier.urihttp://hdl.handle.net/10459.1/56764
dc.description.abstractBackground: Subgroup analyses of clinical studies suggest that bevacizumab plus XELOX is effective and tolerable in elderly patients with metastatic colorectal cancer (mCRC). The prospective BECOX study examined the efficacy and safety of bevacizumab plus XELOX, followed by bevacizumab plus capecitabine in elderly patients with mCRC. Methods: Patients aged X70 years with Eastern Cooperative Oncology Group performance status 0 out of 1 and confirmed mCRC were included. Patients received bevacizumab 7.5 mg kg 1 and oxaliplatin 130 mg m 2 on day 1, plus capecitabine 1000 mg m 2 bid orally on days 1–14 every 21 days; oxaliplatin was discontinued after 6 cycles. The primary end point was time to progression (TTP). Results: The intent-to-treat population comprised 68 patients (65% male, median age 76 years). Median TTP was 11.1 months; median overall survival was 20.4 months; overall response rate was 46%. Grade 3 or 4 adverse events included diarrhoea (18%) and asthenia (16%). Grade 3 or 4 adverse events of special interest for bevacizumab included deep-vein thrombosis (6%) and pulmonary embolism (4%). Conclusions: Bevacizumab plus XELOX was effective and well tolerated in elderly patients in the BECOX study. The adverse-event profile was similar to previous reports; no new safety concerns were identified. Fit elderly patients with mCRC should be considered for treatment with bevacizumab plus XELOX. T.ca_ES
dc.language.isoengca_ES
dc.publisherCancer Research UKca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1038/bjc.2014.346ca_ES
dc.relation.ispartofBritish Journal of Cancer, 2014, núm. 111, p. 241-248ca_ES
dc.rights(c) Cancer Research UK, 2014ca_ES
dc.subjectbevacizumabca_ES
dc.subjectXELOXca_ES
dc.subjectelderlyca_ES
dc.subjectcolorectal cancerca_ES
dc.titleFirst-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX studyca_ES
dc.typearticleca_ES
dc.type.versionpublishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccessca_ES
dc.identifier.doihttps://doi.org/10.1038/bjc.2014.346
dc.date.embargoEndDate10000-01-01


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record